Abstract:Abstract Background : CD19-targeted chimeric antigen receptor T cell (CD19CART) therapy has been shown to be safe and effective for patients with relapsed/ refractory (r/r) diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL). However, there is limited data in other types of B-cell NHLs, especially those with central nervous system (CNS) involvement. Accumulating evidence suggests that using a memory T cell starting population to manufacture CD19CAR T cells improves the efficacy of therapy (Wang et al. Blood;127: 2980). Here we report the results of our Phase 1 trial evaluating CD19CART generated using naïve and stem cell memory (Tn/mem) T cells to treat adult patients with all types of r/r B-NHL (NCT02153580). Methods: Trial eligibility included adult patients (≥18 years) diagnosed with CD19+ r/r B-NHL with Karnofsky performance score (KPS) of ≥70% and adequate organ function. Enrolled patients underwent leukapheresis and their autologous T cells were transduced with a hinge optimized CD19R(EQ)28z/EGFRt+ lentivirus containing a CD28 costimulatory domain and co-expressing truncated epidermal growth factor (EGFRt). All but 1 patient received a fludarabine/cyclophosphamide (Flu/Cy)-based lymphodepletion regimen prior to receiving CD19CART at 1 of 2 dose levels (DL): DL1=200 million (M) and DL2=600M CAR+ T cells. The first patient at DL1 received only Cy lymphodepletion but the decision to add Flu to all subsequent patients was then taken. Dose escalation was per the TEQR study design (Blanchard and Longmate. Contemp Clin Trials; 32;114). Primary objectives were safety and identification of the recommended Phase 2 cell dose (RP2D). Results: Twenty-four participants (pts) with B-NHL underwent leukapheresis. Of these, 22 received their Tn/mem CD19CART products (9 at DL1, 13 at DL2) while 2 did not (1 went to transplant and 1 went to a compassionate use trial) [Table 1]. Median age was 60 years (range 41-81), 10 (45%) were female, 16 (73%) were white and 6 (27%) were Hispanic. Fifteen (68%) had a KPS score of ≥80% at enrollment. Median number of prior therapies was 5.5 (range, 1-15). Treated pts had high grade B-cell lymphoma (HGBCL)/DLBCL (7/22 including 2 Richter's transformation and 1 transformed (t)FL), primary CNS lymphoma (PCNSL) (5/22), MCL (4/22), FL (4/22) and Waldenstrom's macroglobulinemia (2/22). Two pts had active secondary CNS involvement (1 MCL and 1 DLBCL pt) at the time of CAR T cell infusion. There were no dose limiting toxicities (DLTs) or any grade (gr) 3 or higher cytokine release syndrome (CRS) events, but 10 (45%) pts developed gr 2 CRS [Table 2]. Furthermore, 3 (14%) pts experienced gr 3 neurotoxicity that was possibly related to CD19CART cells (headache n=2; [dysphasia, encephalopathy, depressed level of consciousness], n=1). These 3 neurotoxicity events were in patients with PCNSL and were reversible. There was no grade 4 or higher neurotoxicity. There were 12/22 (55%, 90%CI [35%,73%]) best objective responses (OR) of partial (PR) or complete response (CR): 4/9 at DL1 (2 PR, 2 CR) and 8/13 at DL2 (all CR). Notably, among the participants with PCNSL, 3/5 achieved a best OR of CR (DL1 n=1; DL2 n=2). At the time of this analysis, 14/22 pts had progressed, giving a median progression free survival of 5.3 months (90% (CI [2.4, NA]). Nine of 22 pts have died, all from disease progression. The median overall survival has not been reached after a median follow-up time of 21.5 months. CAR T cell peak levels were 17.5%±4.5 (mean ± SE; DL1/200M, N=8) and 14.4%±3.9 (DL2/600M, N=13) (Figure 1 A, B). The 600M dose (DL2) was determined to be the RP2D based on the TEQR design, with the DLT rate of 0.0, 90% confidence limits (0.0, 0.21), as well as activity. Conclusions: This clinical study provides evidence for the safety, feasibility and efficacy of Tn/mem-derived CD19CART preceded by Flu/Cy lymphodepletion for the treatment of r/r B-NHL. We plan to pursue this CAR T cell platform in future B-NHL studies, particularly for CNS lymphoma given the encouraging safety and efficacy of CD19CART in the 5 PCNSL patients. Acknowledgements: The proposal for this protocol was developed at ASH CRTI workshop 2011-2012 by Tanya Siddiqi MD. Figure 1 Figure 1. Disclosures Siddiqi: Oncternal: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Research Funding; Janssen: Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Kite Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Wang: Pepromene Bio, Inc.: Consultancy. Popplewell: Novartis: Other: Travel; Pfizer: Other: Travel; Hoffman La Roche: Other: Food. Herrera: ADC Therapeutics: Consultancy, Research Funding; Tubulis: Consultancy; Merck: Consultancy, Research Funding; Takeda: Consultancy; Gilead Sciences: Research Funding; Kite, a Gilead Company: Research Funding; AstraZeneca: Consultancy, Research Funding; Seagen: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Karyopharm: Consultancy. Budde: Mustang Bio, Inc: Research Funding; Merck, Inc: Research Funding; Amgen: Research Funding; BeiGene: Consultancy; IGM Biosciences: Research Funding; Roche: Consultancy; Gilead: Consultancy; Novartis: Consultancy; AstraZeneca: Research Funding. Nikolaenko: Rafael Pharmaceuticals: Research Funding; Pfizer: Research Funding. Brown: Mustang Bio: Patents & Royalties, Research Funding; Chimeric therapeutics: Patents & Royalties, Research Funding. Forman: Allogene: Consultancy; Lixte Biotechnology: Consultancy, Current holder of individual stocks in a privately-held company; Mustang Bio: Consultancy, Current holder of individual stocks in a privately-held company. OffLabel Disclosure: CD19-directed CAR T cell therapy manufactured at City of Hope being used for relapsed/refractory B-cell NHL.

Abstract CT007: CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas

Abstract CT023: Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma

Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: an Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies

Abstract CT522: Feasibility and safety of a novel CD19 CAR T cell therapy in adults with R/R B-NHL

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

A PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTORMODIFIED T CELLS DIRECTED AGAINST CD19 IN PATIENTS WITH RELAPSED OR REFRACTORYCD19(+) B CELL LYMPHOMAS: INTERIM ANALYSIS

Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Abstract 3198: Fully human CD20 and CD19 dual-targeting CAR-T cells mediate long-term remissions and protection from tumor rechallenge in vivo

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

CD20-Specific Chimeric Antigen Receptor-Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study